Relay Therapeutics (NASDAQ:RLAY) outlined new data and development plans for its lead oncology program, zovegalisib, during a “frontline breast cancer update” conference call, highlighting encouraging ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...
The global pancreatic neuroendocrine tumors (PNETs) market is experiencing significant growth driven by rising incidence rates, advances in diagnostic imaging, and expanding therapeutic options. PNETs ...
The stock is down on a predictable, already-announced Entresto patent cliff (Entresto -42% YoY in Q1) and the market is ...
Oral 5-alpha-reductase inhibitors do not increase the risk for cardiovascular disease in patients treated for androgenetic ...
Lyme disease is the most common tick-borne infectious disease in the United States. Named for the Connecticut town where it was first reported in the 1970s, Lyme is prevalent in the northeast and ...
TrumpRx has signed deals with 86% of the branded drug market. But are prices actually falling for most Americans? A doctor ...
Wages cover the bills. Dividends buy back your time. Earned income stops when you do; portfolio income deposits into your ...
With Xtandi's growth days numbered, an unfazed Astellas expects a group of new products will more than offset the decline of ...
The site represents an important addition to Jamjoom Pharma’s manufacturing network and is expected to enhance its production ...
Researchers conducted a retrospective cross-sectional analysis of patients diagnosed with de novo metastatic breast cancer to evaluate presentation and treatment differences across three main subtypes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results